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 Cataract, defined as an opacity of the lens or lens cap-
sule, is the most common cause of visual impairment in dogs
and humans [1,2]. Phacoemulsification extracapsular cataract
extraction with intraocular lens (IOL) implantation is the most
frequently performed ophthalmic surgical procedure in vet-
erinary and human medicine, with a success rate of greater
than 95% in both species [2,3]. The most common long-term
complication following cataract surgery in both species is
posterior capsule opacification (PCO) [4]. It is well established
that, postoperatively, the primary response of the remaining
anterior lens epithelial cells (LEC) is to undergo epithelial-
mesenchymal transition (EMT)-like changes [5-7]. This re-
sults in posterior migration and proliferation of the LEC with
subsequent vision impairment. EMT refers to a change in phe-
notype from an epithelial to fibrocytic morphology accompa-
nied by aberrant basement membrane synthesis [4-7]. Hall-
marks of EMT include the expression of cyclooxygenase-2
(COX-2), α-smooth muscle actin (α-SMA), lumican, and the
transcriptional repressors Slug and Snail [5,8-10].
PCO-induced decreased visual acuity occurs in up to 50%
of human adults following phacoemulsification surgery, with
a higher risk in younger patients [11-16]. In addition, 100% of
dogs that undergo phacoemulsification cataract surgery de-
velop PCO within one year postoperatively [2,17]. The inci-
dence of PCO in humans has been somewhat lowered, but not
eradicated, by improvements in IOL design, such as the square
edge. Similar IOL implantations are now being used in veteri-
nary patients, and PCO is less severe in these dogs (personal
observation, CMHC). In humans, PCO can be treated effec-
tively with neodymimum:yttrium-aluminum-garnet (Nd:YAG)
laser capsulotomy. However, the cost is substantial, and there
can be significant morbidity due to postoperative complica-
tions including damage to the IOL, cystoid macular edema,
retinal detachment, IOL subluxation, exacerbation of local-
ized endophthalmitis, and retinal detachment [12]. In addi-
tion, YAG laser capsulotomy has not proven successful in ca-
nine patients due to their thicker posterior lens capsules. The
development of alternative methods to prevent PCO is there-
fore of critical importance, and a pharmacologic method of
inhibiting LEC EMT and proliferation would contribute mark-
edly to the success of extracapsular cataract extraction with
IOL placement.
There are three methods commonly used to deliver phar-
macologic reagents to LECs after cataract surgery: (1) direct
injection into the anterior chamber (with or without use of the
Perfect Capsule device); (2) addition to irrigating solutions;
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Purpose: To determine if cyclooxygenase-2 (COX-2) is upregulated when lens epithelial cells (LEC) in clinical samples
of cataracts and posterior capsule opacification (PCO) undergo epithelial-mesenchymal transition (EMT)-like changes.
We also wanted to learn if inhibition of the enzymatic activity of COX-2 could prevent PCO formation.
Methods: To ensure that EMT-like changes were occurring in LEC, real-time RT-PCR was used to examine expression of
EMT markers. Clinical samples of canine cataracts and PCO were examined for COX-2 expression using immunohis-
tochemistry, western blot analysis, and real-time RT-PCR. The COX-2 inhibitors, rofecoxib and celecoxib, were used in
an ex vivo model of PCO formation, and the effects on cellular migration, proliferation, and apoptosis were analyzed
using immunohistochemistry and western blots. Prostaglandin E2 (PGE2) expression was examined with ELISA.
Results: Markers of EMT, such as lumican, Snail, Slug, and COX-2 were expressed in LEC. In clinical samples of
cataracts and PCO, there was overexpression of COX-2 protein and mRNA. Both rofecoxib and celecoxib were effective
at inhibiting PCO formation in our ex vivo model. Prevention of PCO with the COX-2 inhibitors appeared to work
through decreased migration and proliferation, and increased apoptosis. Neither of the drugs had a toxic effect on confluent
LEC and appeared to inhibit PCO through their pharmacologic action. Synthesis of PGE2 was inhibiting in the capsules
treated with the COX-2 inhibiting drugs.
Conclusions: Extracapsular phacoemulsification cataract surgery is the most common surgical procedure performed in
human and veterinary ophthalmology. The most frequent postoperative complication is PCO. The LEC that remain ad-
hered to the lens capsule undergo EMT-like changes, proliferate, and migrate across the posterior lens capsule causing
opacities. We have shown that COX-2, a protein associated with EMT, is upregulated in canine cataracts and PCO.
Inhibiting the enzymatic activity effectively prevented EMT of LEC in our ex vivo model of PCO through pharmacologic
action, and not acute toxicity. These findings indicate that using COX-2 inhibitors in vivo may be an effective technique
in preventing PCO.
Correspondence to: Heather L. Chandler, The Ohio State University,
Veterinary Biosciences, 1900 Coffey Road, Columbus, OH, 43210;
Phone: (614) 292-3551 ext. 48335; FAX: (614) 688-5866; email:
chandler.111@osu.edu
677or (3) impregnation of the IOL. The major difficulty with any
drug delivery system is toxicity to other tissues, especially the
corneal endothelium [18]. A number of pharmacologic agents
have been evaluated for the prevention of PCO formation.
Hypoosmolar agents and antimetabolites, such as catalin,
methotrexate, mitomycin, and 5-fluorouracil, have been shown
to lyse LEC and to be effective in inhibiting PCO in vitro
[19,20]. Unfortunately, in vivo concentrations high enough to
inhibit LEC proliferation, whether delivered as a single appli-
cation or in a sustained release form, have resulted in toxicity
to corneal endothelial cells, irides, ciliary body epithelial cells,
and retina [19]. Topical antiinflammatory medications have
also been evaluated for efficacy in the prevention of PCO.
The nonsteroidal antiinflammatory drug (NSAID) diclofenac
has been shown to inhibit proliferation of subconfluent cul-
tures of LEC in a dose-dependent manner [21]. In vivo, topi-
cal diclofenac used three times daily for one year in human
patients significantly reduced the incidence of PCO [22]. The
use of NSAIDS and corticosteroids for only a month follow-
ing cataract surgery, however, does not significantly inhibit
PCO formation. Based on these findings, further evaluation
of NSAIDS to inhibit PCO in dogs seems warranted.
COX-2 is an immediate early gene induced by a variety
of stimuli, including cytokines, hormones, mitogens, and
growth factors [23-27]. Increasing evidence links
overexpression of COX-2 to EMT during embryonic devel-
opment, fetal implantation, and tumor formation and invasion
[8,28-30]. COX-2 and its metabolic products, such as pros-
taglandin E2 (PGE2), induce inflammation, activate
antiapoptotic and anticell proliferation signaling pathways, and
play a role in carcinogenesis and EMT [8,26,27,30,31]. Se-
lective COX-2 inhibitors like celecoxib have been shown to
be effective in chemoprevention of tumors of epithelial origin
[32-34]. Although several mechanisms are proposed to ex-
plain the antitumor action of COX-2 inhibitors in epithelial
cancers, the effects of these inhibitors on apoptosis and cell
proliferation have been gaining attention [35,36]. Recent stud-
ies demonstrated that the proapoptotic effect of celecoxib is
mediated by caspase-3 activation and that proliferation inhi-
bition by celecoxib is due to downregulation of cyclins, re-
sulting in cell cycle arrest [37,38].
In the present study, we evaluated expression of COX-2
in the normal canine lens and in LEC that have undergone
EMT. We observed increased COX-2 expression in clinical
samples of cataracts and in an ex vivo model of PCO. Spe-
cific COX-2 inhibitors effectively inhibited EMT of LEC in
vitro by decreasing migration and proliferation and increas-
ing apoptosis. We further demonstrated that the effects of COX-
2 inhibitors were due to pharmacological activity rather than
to acute toxicity. These findings suggest that COX-2 inhibi-
tors may effectively eliminate postsurgical PCO in the dog.
METHODS
Samples:  Normal eyes were obtained by enucleation from
dogs in good general health that were humanely euthanized at
a local animal shelter for population control purposes. All dogs
used in this study were estimated to be between 1 and 8 years
of age, based on dentition and thickness of the anterior lens
capsule. Globes were collected within 1 h of death and placed
in 2% betadine solution, then rinsed and immersed in 1X phos-
phate buffered saline solution (PBS, pH 7.2) until dissection,
which was performed within 2 h of enucleation.
Normal whole lenses:  Whole lens capsules were dissected
using a method described in reference [39], then immediately
fixed in neutral-buffered 10% formalin, paraffin embedded,
and sectioned. Routine hematoxylin and eosin (H&E) stain-
ing was performed to assess the orientation of the specimens;
12 samples were selected for immunohistochemical staining
and 24 samples were frozen, either for protein extraction
(n=12) or RNA extraction (n=12).
Primary canine lens epithelial cell cultures:  Anterior lens
capsules with adherent LEC were incubated in trypsin (1X
EDTA, Gibco, Carlsbad, CA) for 5 min at 37 °C, and the su-
pernatants were centrifuged to pellet LEC; LEC were then
resuspended in DMEM (Gibco) and cultured in laminin-coated
flasks (Beckton Dickinson, Franklin Lakes, NJ). LEC were
examined daily to evaluate viability. Just prior to reaching
confluence, they were replated.
Anterior capsules with lens epithelial cells undergoing
epithelial-mesenchymal transition:  Anterior lens capsulotomy
specimens were acquired from dogs with naturally occurring
cataracts prior to routine phacoemulsification cataract extrac-
tion. Samples were obtained during continuous curvilinear
capsulorrhexis and placed in 10% neutral-buffered formalin
(n=20) or snap frozen and stored at -70 °C until protein (n=20)
or RNA extraction (n=30) could be performed. Six whole cata-
ractous lenses from canine patients with anterior lens luxations
and three enucleated globes with naturally occurring PCO due
to previous cataract surgery were fixed in 10% neutral-buff-
ered formalin. Fixed lens samples were embedded in paraffin,
sectioned at 4-5 µm, and stained with H&E. Samples were
examined by light microscopy to determine if there were suf-
ficient cells to allow immunohistochemical staining. For im-
munohistochemical staining, suitable sections were mounted
onto charged slides (ProbeOn Plus, Fisher Scientific, Pitts-
burgh, PA).
Sham cataract surgery and lens capsule harvesting:
Freshly enucleated canine globes were used for this proce-
dure. A 22 gauge needle was employed to begin the routine
continuous curvilinear capsulorrhexis, which was performed
using Utrada forceps. The lens nucleus and cortex were re-
moved intact through the capsulotomy site and an irrigation/
aspiration cannula was used to remove residual cortex from
the lens capsule. The lenticular zonules were severed using
Vannas scissors, and the lens capsule was gently excised from
its vitreal attachments. The lens capsule was then placed in a
sterile petri dish with the capsulotomy side up and pinned into
place using four evenly spaced entomology pins. Five ml of
DMEM containing antibiotic and antimycotic (Gibco,
Carlsbad, CA) was added to the cavity formed by the immo-
bilized lens capsule.
Scratch model to induce epithelial-mesenchymal transi-
tion-like changes:  LEC cultures were allowed to grow to 90%
confluence in unsupplemented DMEM in a six-well laminin
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coated culture dish before a 1 mm scratch was made on the
cellular surface. Cells were allowed to recover for 1, 2, 4, 8,
or 24 h before being harvested for RNA isolation.
Drug treatments:  Celecoxib and rofecoxib were gener-
ously provided by Drs. C.-S. Chen and S. Kulp at The Ohio
State University, College of Pharmacy. Both drugs were dis-
solved in DMSO then diluted to final working concentrations
of 10 and 20 µM, respectively, in DMEM. To determine if the
drugs could prevent EMT-like changes in vitro, we plated LEC
cultures in a six-well laminin-coated culture dish. Cultures
were grown in unsupplemented DMEM and treated with 10
or 20 µM rofecoxib, celecoxib, or vehicle and allowed to reach
to 90% confluence. Six culture wells were treated with each
drug dose. A 1 mm scratch was created and cells were allowed
to recover for 24 h before being harvested for protein isola-
tion. Digital images were taken immediately following the
scratch and 24 h following wound healing. Images were up-
loaded and migration was quantified using Adobe Photoshop
Version 6.0.
To determine if the drugs could prevent PCO, capsules
were harvested as described in the previous paragraph and
treated immediately. Every third day, the capsules (n=6) were
given fresh media and drug. Control capsules received fresh
media with vehicle (DMSO) only. LEC growth on capsules
was monitored by digital photography every other day. Fol-
lowing 14 days, capsules were dissected into two pieces: Half
of the pieces were placed in 10% neutral-buffered formalin
and half were frozen for protein extraction. Histopathology
with routine H&E staining was performed on half of the lens
capsule. Cells still attached to the capsule were counted on
the H&E slides.
To determine if LEC could recover the ability to undergo
EMT following treatment with celecoxib or rofecoxib, we im-
mediately treated six capsules with 20 µM celecoxib or
rofecoxib following dissection. After seven days, treatment
medium was replaced with medium containing vehicle only
for the following seven days. Capsule morphology was moni-
tored using phase contrast microscopy and photomicrographs.
After 14 days, capsules were dissected into two pieces: Half
went into 10% neutral-buffered formalin for subsequent his-
tology, and half were frozen for protein extraction.
To determine if the drugs were acutely toxic to LEC, cap-
sules were treated with vehicle for the first seven days. After-
wards, the capsules were treated with 20 µM celecoxib or
rofecoxib for seven days. Capsules were monitored by phase
contrast microscopy and digital photomicrography every other
day. After 14 days, capsules were dissected into two pieces;
half of these were placed in 10% neutral-buffered formalin,
and half were frozen for protein extraction. LEC were exam-
ined for markers of apoptosis using immunohistochemistry
against cleaved caspase-3 and TUNEL staining.
Antibodies:  Immunohistochemical staining was per-
formed using antibodies against COX-2 (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA), cleaved caspase-3 (1:20;
Oncogene, San Diego, CA), α-SMA (1:100; Spring Bio-
science, Freemont, CA), and PCNA (1:200; DAKO Corp.,
Carpinteria, CA). Secondary antibodies included, as appro-
priate, antigoat (Vector Laboratories, Burlingame, CA),
antirabbit (Biogenex Super Sensitive Link; Biogenex, San
Ramon, CA), and antimouse (Vector) antibodies. DAKO An-
tibody Diluent with Background Reducing Components
(DAKO) was used to dilute antibodies.
Immunohistochemical staining:  Standard avidin-biotin
complex (ABC) immunohistochemistry was performed.
Briefly, decerated paraffin-embedded sections were incubated
with antigen retrieval solution (DAKO) at 90 °C for 20 min
and allowed to cool to room temperature for 20 min. All sub-
sequent steps were performed at room temperature. Samples
were treated with peroxidase block (DAKO) for 10 min,
washed with 1X Tris buffered saline containing 0.1% Tween
20 (TBST), then incubated in protein block for 20 min
(DAKO). Primary antibodies were applied to slides for 1 h at
room temperature. After slides were washed in TBST, sec-
ondary antibodies were applied for 1 h at room temperature.
Slides were washed in 1X TBST, then incubated in ABC (Vec-
tor Laboratories) for 1 h. Following washes in 1X TBST,
immunostaining was then visualized with either
diaminobenzidine tetrahydrochloride (DAB; DAKO) applied
for 3 min at room temperature in the dark or with Vector
NovaRED (Vector Laboratories) applied for 5 min at room
temperature. Following washes, slides were counterstained
with hematoxylin, dehydrated, and permanently mounted.
Stained samples were visualized by light microscopy and pho-
tographed (Olympus; Melville, NY). Positive controls con-
sisted of canine squamous cell carcinoma and canine mam-
mary gland tumors. Negative controls omitted the primary
antibody. Controls were performed concurrently with each
batch of slides.
TUNEL staining:  Apoptosis was detected in treated cap-
sules by the TUNEL assay (Apoptosis Detection System with
fluorescein; Promega Corp., Madison, WI). Decerated paraf-
fin-embedded sections were treated with proteinase K (20 mg/
ml) for 10 min at room temperature, washed, fixed in 4%
methanol-free formaldehyde solution for 5 min, and covered
with equilibration buffer. Terminal deoxynucleotidyl trans-
ferase-buffer containing nucleotide mix was applied to the
sections for 60 min at 37 °C in a moist chamber. The sections
were washed and counterstained with propidium iodide.
Immunoblot analysis:  Whole cell protein was extracted
from frozen normal canine anterior lens capsules and anterior
capsulotomy samples from clinical canine cataracts using 1X
CHAPs lysis buffer (Chemicon, Temecula, CA). Samples in
CHAPs buffer were incubated on ice for 30 min, then centri-
fuged at 12,000x g for 20 min. Five µl of the resulting super-
natant was used for quantification of protein concentration by
Bradford protein assay (Bio-Rad, Hercules, CA); the remain-
der was stored at -80 °C until used.
Samples were denatured (95 °C, 3 min) in modified so-
dium dodecyl sulfate (SDS) sample loading buffer, and pro-
tein (15 µg) was separated by SDS/PAGE (10% acrylamide,
v/v) at 150 V for approximately 1.5 h. After electrophoresis,
proteins were transferred to a nitrocellulose membrane at 300
mA for 1.5 h. Nonspecific binding was blocked by incubating
the membrane for 5 h at room temperature in 5% nonfat dry
679milk diluted in 1X TBST. After blocking, membranes were
incubated overnight with a goat anti-COX-2 antibody (Santa
Cruz) that had been diluted 1:500 in blocking solution. The
membrane was then washed extensively (5x10 min) with 1X
TBST, and secondary antibody (antigoat immunoglobin; Vec-
tor Laboratories) was added in blocking solution (1:10,000)
for 1 h at room temperature. Protein was detected using the
Pierce (Rockford, IL) Femto Immunoblotting system and
Kodak X-OMAT AR film. Membranes were stripped (Restore
stripping solution, Pierce) and the technique was repeated us-
ing antibeta-actin antibody (1:5000; Sigma, St. Louis, MO) as
a loading control.
Quantitative RT-PCR:  Total RNA was extracted using
Absolutely RNA Microprep Kit (Stratagene, La Jolla, CA) as
suggested by the manufacturer. The ImProm II Reverse Tran-
scriptase kit (Promega) was used to synthesize the first strand
cDNA as per the manufacturer’s instructions. Quantitative real-
time RT-PCR was performed in the Stratagene Mx3000p
Multiplex Quantitation System as follows: 95 °C for 15 min,
then 40 cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for
30 s, using the QuantiTect SYBR Green PCR kit (Stratagene).
Primers to amplify sequences of the canine COX-2 and HPRT
(housekeeping control) genes were designed based on clon-
ing and sequence data obtained in our laboratory. The primers
used are presented in Table 1.
Real time RT-PCR was repeated 3 times on each sample.
The relative amounts of COX-2 mRNA, normalized to HPRT
levels, were calculated according to the method described by
Ramakers [40]. Results were expressed as the ratio of target
gene to HPRT gene expression.
Quantitation of PGE2 levels:  Tissue culture media was col-
lected from lens capsules treated with vehicle, rofecoxib, or
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Figure 2. Expression of COX-2 in normal canine LEC and in LEC
undergoing EMT-like changes.  A: In normal LEC there is little to no
COX-2 immunoreactivity, while LECs in cataractous and PCO sample
show marked cytoplasmic staining for COX-2, as indicated by dif-
fuse brown cytoplasmic staining. The scale bar is equal to 30 µm. B:
Western blot analysis of COX-2 in normal canine LEC and in LEC
undergoing EMT-like changes. In normal LEC (dog 1 and 2) there is
little COX-2 protein present, while in clinical samples of cataract
and PCO (dog 3 and 4) there is increased expression of COX-2 pro-
tein. C: Using real-time RT-PCR, expression of COX-2 mRNA was
analyzed. In normal LEC there is some expression of COX-2 mRNA,
while in clinical samples of cataract and PCO there is a significant
(p<0.0145) upregulation of COX-2. Error bars indicate SEM.
Figure 1. Expression of markers of EMT in LEC.  A 1 mm scratch
was created in confluent LEC and allowed to heal before real-time
RT-PCR was used to determine expression. Lumican is upregulated
early in EMT and expression peaks by 2 h before returning to basal
expression by 4 h. Expression of the Snail in LEC peaks by 4 h and
Slug expression peaks by 8 h. Both Snail and Slug return to basal
expression by 24 h.
680celecoxib and snap-frozen in liquid nitrogen. PGE2 levels were
assessed using the PGE2 ELISA kit from Cayman Chemical
(Ann Arbor, MI) according to the manufacturer’s instructions.
RESULTS
Markers of epithelial-mesenchymal transition are expressed
in lens epithelial cells:  Using real-time RT-PCR, we exam-
ined the expression of markers of EMT-like changes in our
canine LEC scratch model. Lumican expression peaked 2 h
following the wounding event and returned to basal expres-
sion by 4 h (Figure 1). By 4 h, Snail expression peaked and
reached basal expression in 24 h (Figure 1). Slug expression
remained at basal levels until peaking at 8 h before decreasing
expression at 24 h (Figure 1). In support of other studies, this
data provides evidence that EMT-like changes occur in ca-
nine LEC.
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Figure 3. Effects of rofecoxib and celecoxib in migrating LEC in vitro.  A: Cells were treated with 10 or 20 µM rofecoxib, celecoxib, or vehicle
before a 1 mm scratch was created and LEC were allowed to heal for 24 h. Both rofecoxib and celecoxib treated LEC had decreased rates of
wound closure compared to the control. There was a dose dependent response to drug treatment. The scale bar is equal to 0.5 mm. B: There
was significantly (p<0.001) decreased healing in LEC cultures treated with either celecoxib or rofecoxib compared to controls. C: Western
blot analysis of the LEC treated with 20 µM rofecoxib or celecoxib. There is increased expression of COX-2 in control LEC undergoing EMT-
like changes, and decreased expression in LEC treated with the COX-2 inhibitors. There is no expression of COX-2 in rofecoxib treated cells
while there is still some COX-2 protein present in the celecoxib treated cells.
681Cyclooxygenase-2 expression in the canine lens:  There
was minimal COX-2 immunoreactivity in the normal dog eye,
and this was restricted to the epithelium of the ciliary body.
The LEC of canine cataractous capsulotomy and PCO samples
had diffuse cytoplasmic COX-2 immunoreactivity, while the
LEC of normal canine lenses were COX-2-negative (Figure
2A). Western immunoblotting and quantitative RT-PCR con-
firmed that LEC from clinical cataract samples had increased
COX-2 protein and mRNA expression compared to normal
LEC (Figure 2B,C). Normal LEC expressed significantly lower
(p<0.0145) levels of COX-2 mRNA and protein than catarac-
tous LEC. Taken together, these results indicated COX-2 ex-
pression was upregulated in LEC undergoing EMT.
Effects of cyclooxygenase-2 inhibitors on epithelial-mes-
enchymal transition of lens epithelial cells:  To determine if
COX-2 inhibition would prevent EMT-like changes in LEC,
we allowed primary cultures of normal canine LEC to grow
to 95% confluence. A 1 mm scratch wound was then created
and cultures were treated with either vehicle, 10 µM rofecoxib
or celecoxib, or 20 µM rofecoxib or celecoxib. After 24 h,
wounds in the vehicle-treated cultures had closed, while the
wounds in the rofecoxib and the celecoxib-treated cultures
remained open (Figure 3A). There was a significant (p<0.001)
delay in LEC migration in both the celecoxib and rofecoxib
treatments compared to the controls (Figure 3B).
Immunoblotting revealed that COX-2 expression was de-
creased in the rofecoxib- and celecoxib-treated cultures com-
pared to vehicle-treated cultures (Figure 3C). Rofecoxib ap-
peared to inhibit COX-2 expression more effectively than
celecoxib.
Effects of cyclooxygenase-2 inhibitors on posterior cap-
sule opacification formation:  Following sham cataract sur-
gery, canine lens capsules with residual LEC present on the
anterior lens capsule were treated with vehicle alone for 2
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Figure 4. EMT-like changes in the
ex vivo lens capsule model.  Fol-
lowing sham cataract surgery, ca-
nine lens capsules with residual
LEC present on the anterior lens
capsule were treated with vehicle
alone for 2 weeks. By the end of this
period, LEC were present on the
anterior capsule (a) and had mi-
grated across the posterior lens cap-
sules (p; A and B). These LEC were
immunopositive for COX-2, PCNA,
and α-SMA (C-E, respectively). To
evaluate apoptosis, capsules were
stained for cleaved caspase-3 (F).
The scale bars are equal to 20 µm,
except for B, where the scale bar is
equal to 50 µm.
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Figure 5. Effect of rofecoxib on EMT in LEC.  In
canine lens capsules treated for 2 weeks with 10 µM
rofecoxib immediately following sham cataract sur-
gery, remaining LEC had altered morphology and
adhesion (A and B). Magnification 40X. “a” indicates
the anterior capsule and “p” indicates the posterior
capsule. Immunohistochemistry revealed little or no
staining for COX-2, decreased expression of PCNA
and α-SMA, and increased expression of cleaved
caspase-3 (C-F, respectively). Bars, 20 µm. Western
blot analysis of the LEC treated with 10 µM
Rofecoxib following sham cataract surgery (G).
COX-2 protein was decreased in rofecoxib-treated
capsules compared to vehicle-treated capsules.
683weeks. By the end of this period, LEC had migrated across
the posterior lens capsules (Figure 4A,B). These LEC were
immunopositive for COX-2, PCNA, and α-SMA, indicating
that the cells were both migrating and proliferating (Figure
4C-E). There was minimal immunoreactivity for cleaved
caspase-3, indicating that LEC were not undergoing apoptosis
(Figure 4F). The absence of TUNEL positivity confirmed
caspase-3 findings (data not shown). In addition, western
immunoblot analysis revealed increased COX-2 expression.
Changes seen in cultured canine LEC following sham cata-
ract surgery were similar to the EMT changes seen in clinical
cases of PCO formation. Thus our ex vivo model mimics clini-
cal PCO formation.
In canine lens capsules treated with 10 µM rofecoxib for
two weeks immediately following sham cataract surgery, LEC
were vacuolated and did not adhere normally to the underly-
ing lens capsule (Figure 5A,B). Immunohistochemistry re-
vealed little or no staining for COX-2, increased expression
of cleaved caspase-3, and decreased expression of PCNA and
α-SMA (Figure 5C-E). Results from the TUNEL assay con-
firmed the caspase-3 staining, revealing increased numbers of
positive cells, both indicating increased apoptosis (data not
shown). As determined by western immunoblot analysis, COX-
2 protein was decreased in rofecoxib-treated capsules com-
pared to vehicle-treated capsules (Figure 5G). There were few
LEC in lens capsules treated with 20 µM rofecoxib for 2 weeks
(Figure 6A,B). The LEC present were highly vacuolated and
did not adhere to the adjacent basement membrane. Due to
the low numbers of LEC in these samples, immunohistochem-
istry and western immunoblot analysis were not performed.
The number of cells adherent to the lens capsule were counted
from an H&E hematoxylin and eosin slide. There were sig-
nificantly fewer cells (p<0.001) present in the rofecoxib-treated
groups compared to the vehicle controls (Figure 7).
Following sham cataract surgery, canine lens capsules
treated with 10 µM celecoxib for two weeks also had vacu-
olated LEC that did not adhere to the underlying basement
membrane (Figure 8A,B). Immunohistochemical staining re-
vealed that the remaining LEC (1) expressed a moderate
amount of COX-2, (2) were strongly immunoreactive for
cleaved caspase-3, (3) did not express PCNA, and (4) showed
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Figure 6. Effects of high doses of rofecoxib on EMT in LEC.  There were very few LEC in lens capsules treated with 20 µM rofecoxib for 2
weeks. The LEC present were highly vacuolated and did not adhere to the adjacent basement membrane as seen in phase contrast microscopy
(A, Bar, 20 µm) and histology (B, Bar 50 µm).
Figure 7. Number of cells adhered to the lens capsule following treat-
ment with rofecoxib or celecoxib.  Cells were counted from a hema-
toxylin and eosin stained slide of 6 different lens capsules in each
treatment group. There was a significant decrease (p<0.001) in the
number of cells present in the celecoxib and rofecoxib treated groups
compared to the vehicle controls.
684decreased α-SMA immunostaining compared to untreated
capsules (Figure 8C-F). As with the rofecoxib-treated capsules,
there was an increase in the number of TUNEL positive cells
(data not shown). Western blotting confirmed COX-2 protein
was decreased in the celecoxib-treated capsules compared to
the vehicle-treated capsules (Figure 8G). Lens capsules treated
with 20 µM celecoxib for two weeks were devoid of all LEC
(Figure 9A,B). A count of cells still adhered to the lens cap-
sule revealed a significant decrease (p<0.001) in the celecoxib-
treated groups compared to the controls (Figure 7).
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Figure 8. Effects of celecoxib on EMT
in LEC.  Following sham cataract sur-
gery, canine lens capsules treated with
10 µM celecoxib for 2 weeks had some
remaining LEC with altered morphol-
ogy and adhesion (A and B). Magnifi-
cation 40X. “a” indicates the anterior
capsule and “p” indicates the posterior
capsule. Immunohistochemical stain-
ing revealed that the remaining LEC
expressed a moderate amount of COX-
2, did not express PCNA, showed de-
creased α-SMA immunostaining, and
were strongly immunoreactive for
cleaved caspase-3 compared to un-
treated capsules (C-F, respectively).
Bars, 20 µm. Western blot analysis of
the LEC treated with 10 µM celecoxib
following sham cataract surgery (G).
COX-2 protein was decreased in
celecoxib-treated capsules compared
to vehicle-treated capsules.
685Prostaglandin E2 expression following treatment with
rofecoxib or celecoxib:  To determine if COX-2 inhibition was
reflected in reduced synthesis of its products, expression of
PGE2 was evaluated. We found that synthesis of PGE2 was
significantly decreased (p<0.0001) in canine capsules that were
treated with rofecoxib or celecoxib compared with vehicle-
treated capsules (Figure 10).
Evaluating recoverability in treated lens epithelial cells:
LEC on capsules treated with drug for one week were allowed
to recover in vehicle-only medium for a second week. As
shown previously, EMT was inhibited when LEC were incu-
bated in either rofecoxib or celecoxib during the first week of
culture. Because the capsules were treated with the drugs for
only one week, as compared to two weeks in our previous
experiments, some LEC remained on the capsule. This allowed
us to determine if the LEC could repopulate the capsule. More-
over, even after one week of culture in the absence of drug,
the LEC did not regain the ability to adhere to the lens capsule
and proliferate and undergo EMT (Figure 11A-D). The num-
ber of cells adhered to the lens capsule were counted from a
H&E slide. There was a significant decrease (p<0.001) in the
number of cells present in either the rofecoxib- or celecoxib-
treated groups compared to the vehicle controls (Figure 12).
Evaluating the toxic effects of rofecoxib and celecoxib:
In an attempt to determine if the effects of rofecoxib or
celecoxib were due to specific pharmacologic activity or to
nonspecific chemical toxicity, we performed sham cataract
surgery and treated LEC with vehicle only for one week, dur-
ing which time EMT occurred as seen previously. Lens cap-
sules were then treated with 20 µM rofecoxib or celecoxib for
a second week. LEC in these samples did not exhibit any
morphologic signs of nonspecific toxicity. After a week of
culture in the presence of inhibitor, LEC remained adherent to
the underlying capsule (Figure 13A-D) and were negative for
cleaved caspase-3 and TUNEL (data not shown). A count of
cells still adhering to the lens capsule revealed no significant
decrease in the rofecoxib- or celecoxib-treated groups com-
pared to the controls (Figure 12). These findings suggested
that both drugs inhibited PCO through their pharmacologic
actions rather than by non-specific toxicity. However, inhibi-
tion of EMT by the drugs appeared to be irreversible.
DISCUSSION
 Remaining LEC on the anterior lens capsule following extra-
capsular lens extraction in rabbits and humans initially prolif-
erate and, by four days after cataract surgery, undergo EMT
[11,41]. LEC at the equatorial lens bow migrate posteriorly to
©2007 Molecular Vision Molecular Vision 2007; 13:677-91 <http://www.molvis.org/molvis/v13/a74/>
Figure 9. Effects of high doses of celecoxib on EMT in LEC.  Lens capsules treated with 20 µM celecoxib for 2 weeks were devoid of all LEC
on the anterior (a) and posterior (p) capsules as seen through phase contrast microscopy (A, the scale bar is equal to 20 µm) and histology (B,
the scale bar is equal to 50 µm).
Figure 10. Expression of PGE2 in LEC treated with 10 µM rofecoxib
or celecoxib for 2 weeks.  Synthesis of PGE2 was significantly de-
creased (p<0.0001) in canine capsules that were treated with rofecoxib
or celecoxib compared with vehicle-treated capsules.
686populate the posterior capsule, a markedly abnormal location
[12,42]. In ex vivo cultures of canine lens capsules, LEC mi-
grate across the majority of the posterior lens capsule by 14
days following sham cataract surgery, a situation that mimics
PCO formation in vivo [43]. The EMT that occurs during PCO
formation appears to be initiated by signals originating from
outside the epithelial cell, including extracellular matrix com-
ponents such as collagen and soluble growth factors [44-46].
Activation of TGF-β and EGF signaling pathways are suffi-
cient to induce EMT-like changes in LEC, and these path-
ways have been shown to be involved in cataractogenesis and
PCO formation [18,47-51]. Injured LECs at capsulotomy edges
show enhanced expression of EGF receptors, increasing their
responsiveness to EGF in the aqueous humor [52]. Thus,
growth factor-driven changes in cell phenotype may play an
important role in the cell migration and EMT that character-
ize PCO.
Many factors in the cataract extraction process influence
PCO severity, including capsulorrhexis technique, use of
hydrodissection, composition of the irrigating solution, and
type of intraocular lens prosthesis [12,17,53,54]. None of the
currently used techniques of cataract surgery completely elimi-
nates the risk of PCO formation. Nd:YAG laser posterior
capsulotomy is the most commonly used therapeutic modal-
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Figure 11. Evaluating the recoverability of LEC following COX-2 inhibition.  LEC on capsules treated with drug for one week and were
allowed to recover in medium containing vehicle only for a second week. LEC that were incubated in either celecoxib (A and B) or rofecoxib
(C and D) during the first week of culture did not undergo EMT. The scale bars are equal to 30 µm (A and C) and to 50 µm (B and D).
Figure 12. Cell counts to evaluate recoverability and toxicity follow-
ing COX-2 inhibition.  Cells were counted from a hematoxylin and
eosin stained slide of 6 different lens capsules in each treatment group.
There is a significant decrease (p<0.001) in the number of cells ad-
hered to the lens capsule following treatment with the COX-2 inhibi-
tors for week 1 before capsules were treated with vehicle for week 2.
There was no significant decrease in the number of cells present in
the capsules that received vehicle for week 1 and the COX-2 inhibi-
tor for week 2 compared to the vehicle controls.
687ity for treatment of PCO. Even minimal haze in humans may
require secondary capsulotomy. This procedure cost the United
States Medicare Program 250 million dollars in 1993 [55]. A
2001 study found that 3.6 billion dollars were spent on cata-
ract-related eye care [56]. As well, younger individuals are
predisposed to PCO development. A 1989 study determined
that 70% of patients under 40 years old require a second
Nd:YAG laser capsulotomy compared to 37% of patients older
than 60 years [57]. In chronic PCO lesions, the mechanical
forces of pseudometaplastic LEC contraction, caused by ex-
pression of α-SMA, can lead to striae or folds in the posterior
capsule and to IOL decentration as well as anterior capsule
contracture syndrome [12]. The capsulotomy procedure per-
formed to treat PCO is not without its own potential compli-
cations, including damage to the IOL, intraocular pressure el-
evation, cystoid macular edema, retinal detachment, IOL lux-
ation, and endophthalmitis [12].
COX-2 is an inducible enzyme normally undetectable in
most cell types [58]. COX-2 is involved in the immediate-
early gene response to cytokines and growth factors, such as
EGF [59]. We have discovered cataractous LEC that have
undergone EMT express COX-2 mRNA and protein, but nor-
mal LEC do not. An abundance of evidence now exists dem-
onstrating a role for COX-2 in EMT. For example, one of the
products of COX-2 activity, PGE2, has been shown to be a
critical player mediating the development of cancer. PGE2
stimulates increased proliferation, altered adherence, increased
migration, and enhanced invasiveness of cancer cells [60-63].
Our study demonstrated that inhibition of COX-2 with
celecoxib and rofecoxib in an ex vivo model of PCO results in
decreased PGE2 production by LEC and decreased prolifera-
tion and increased apoptosis of LEC.
Other studies have found that COX-2 prevention of pro-
liferation was dose-dependent and mediated through inhibi-
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Figure 13. Evaluating the toxic effects of celecoxib and rofecoxib on LEC not undergoing EMT.  To determine if the effects of rofecoxib or
celecoxib were due to specific pharmacologic activity or to non-specific chemical toxicity, sham cataract surgery was performed and LEC
were treated with vehicle only for one week, then treated with 20 µM celecoxib (A and B) or rofecoxib (C and D) for a second week. There
were no signs of toxicity in the LEC. The scale bars are equal to 30 µm (A and C) and to 50 µm (B and D).
688tion of cell-cycle progression, particularly through tight regu-
lation of the G1-S checkpoint, controlled by cyclin D1 and
cyclin E [37]. While our study did not examine the specific
mechanism through which celecoxib exerts its effects on cell-
cycle regulation, we have provided evidence that EMT-like
changes in LEC are inhibited by celecoxib at least in part
through decreased cellular proliferation. In the present study,
we also demonstrate that celecoxib induction of apoptosis re-
sults in increased expression of cleaved caspase-3. Several
other studies support this finding and indicate that celecoxib-
induced apoptosis may be mediated through activation of a
caspase pathway [37,38]. Alternatively, celecoxib may pro-
mote apoptosis through the PDK1 pathway, with subsequent
inhibition of Akt [36]. It has been reported that rofecoxib has
no appreciable effects on Akt signaling in relation to apoptosis
[64]. Our data suggest that celecoxib is a more potent inhibi-
tor of PCO formation ex vivo, potentially through the increased
Akt regulated apoptosis. Studies are currently being performed
in our laboratory to evaluate the role of Akt in PCO forma-
tion. Because increased cell proliferation and resistance to
apoptosis contribute to PCO formation, simultaneously coun-
teracting multiple processes provides a more effective approach
toward preventing secondary cataractogenesis.
The data presented here suggest that there is a feedback
mechanism for the regulation of COX-2 expression. This is
supported by other studies that have found a positive feed-
back cycle between two systems: one that involves COX-2
synthesis of PGE2, the other involving aromatase control over
estrogen synthesis [65,66]. Although the mechanisms are not
fully understood, estrogen can induce expression of COX-2
and subsequently of PGE2 through induction of various
cytokines and growth factors. High levels of PGE2 can then
induce aromatase activity, which controls estrogen synthesis
[65,66]. Preliminary data obtained in our laboratory indicate
that LEC undergoing EMT, have increased expression of es-
trogen and higher levels of aromatase activity compared to
normal LEC [67]. This is one potential mechanism by which
COX-2 expression may be controlled in canine cataract and
PCO samples and further supports the use of COX-2 inhibi-
tors to prevent EMT of LEC.
Intraocular application of pharmacologic agents to pre-
vent PCO has been investigated by several authors with the
goal of selectively destroying LEC while avoiding toxic side
effects on other intraocular tissues. Corneal endothelial toxic-
ity is a major concerns when intraocular drugs are used. Pre-
liminary data from our laboratory indicate that neither
celecoxib nor rofecoxib is toxic to corneal endothelial cells,
based on cell morphology and the absence of caspase-3 stain-
ing. Moreover, because there is little basal expression of COX-
2 within the normal eye, the use of COX-2 inhibitors to pre-
vent PCO formation is unlikely to affect the eye adversely.
Other studies support our present finding that COX-2 expres-
sion in the normal canine eye is restricted to low levels in the
ciliary body epithelium [68-70]. In addition, the data presented
here suggest that celecoxib and rofecoxib have few toxic ef-
fects on LEC not undergoing EMT, thus these drugs may be
safe for nonmigrating cells. While we recognize that rapidly
dividing cells may be more susceptible to toxicity than quies-
cent confluent cells, we believe that early treatment of LEC
undergoing EMT provides a potentially effective yet safe treat-
ment for PCO.
It remains to be determined if simply flushing the cap-
sule during or immediately following cataract surgery with
either celecoxib or rofecoxib will be sufficient to inhibit PCO
formation or if extended drug release will be necessary. We
are currently examining many options for incorporating COX-
2 inhibitors into current PCO prevention strategies, including
long-term topical application of celecoxib or rofecoxib and
impregnating IOL with the drugs for release over time. Pre-
liminary data are promising, and suggest that both celecoxib
and rofecoxib effectively prevent PCO formation and aid in
controlling postoperative inflammation.
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